meropenem and Bordetella-Infections

Bordetella bronchiseptica is a gram-negative, obligate aerobic coccobacillus known to cause disease in domesticated animals and pets. In humans, B. bronchiseptica commonly leads to respiratory infections like pneumonia or bronchitis, and animal contact usually precedes the onset of symptoms.. We report a case of post-traumatic B. bronchiseptica meningitis without recent surgery in the setting of immunosuppression with a monoclonal antibody. Our case concerns a 77-year-old male with ulcerative colitis on infliximab who sustained a mechanical fall and developed a traumatic cerebrospinal fluid leak complicated by meningitis. He received meropenem then ceftazidime during his hospital course, and temporary neurosurgical drain placement was required. His clinical condition improved, and he was discharged at his baseline neurological status.. B. bronchiseptica is an unusual cause of meningitis that may warrant consideration in immunocompromised hosts with known or suspected animal exposures. To better characterize this rare cause of meningitis, we performed a systematic literature review and summarized all previously reported cases.

Topics: Aged; Animals; Anti-Bacterial Agents; Bordetella bronchiseptica; Bordetella Infections; Ceftazidime; Cerebrospinal Fluid Leak; Colitis, Ulcerative; Drainage; Humans; Immunocompromised Host; Immunosuppressive Agents; Infliximab; Male; Meningitis; Meropenem; Neurosurgical Procedures; Treatment Outcome

Topics: Aged; Aged, 80 and over; Bordetella bronchiseptica; Bordetella Infections; Bronchitis; Fatal Outcome; Female; Humans; Injections, Intravenous; Meropenem; Recurrence; Sputum; Thienamycins

The in vitro activities of levofloxacin, ofloxacin, d-ofloxacin, ciprofloxacin, cefpirome, and meropenem against 34 clinical isolates each of Bordetella pertussis and Bordetella parapertussis were determined by agar dilution on Mueller-Hinton agar supplemented with 5% horse blood. Levofloxacin was as active as ciprofloxacin against both species (MIC, 0.06 microgram/ml) and more active than ofloxacin and d-ofloxacin. Cefpirome was more active against B. pertussis (MIC, 1.0 microgram/ml) than against B. parapertussis (MIC, > 2 micrograms/ml), while the reverse was true for meropenem (MIC, 2.0 micrograms/ml against B. pertussis and 1.0 microgram/ml against B. parapertussis).

Topics: Anti-Infective Agents; Bordetella; Bordetella Infections; Bordetella pertussis; Cefpirome; Cephalosporins; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Thienamycins; Whooping Cough